ChemiCare has secured €2.5 million in seed funding to advance its innovative drug pipeline for rare and autoimmune diseases, spearheaded by its lead compound CIC-39 targeting Duchenne Muscular Dystrophy.

Target Information

ChemiCare, an innovative spin-off from the University of Eastern Piedmont (UPO), has successfully completed a €2.5 million seed funding round. This investment round was backed by prominent firms including CDP Venture Capital SGR S.p.A., Bio4Dreams S.p.A., and Bridge4Pharma S.r.l., aimed at advancing ChemiCare's internal drug development pipeline. The company focuses on developing groundbreaking therapies for rare and autoimmune diseases. With the expertise of co-founders Tracey Pirali in Medicinal Chemistry and Beatrice Riva in Pharmacology, ChemiCare is positioning itself as a key player in addressing significant medical needs within niche therapeutic areas.

ChemiCare is currently engaged in clinical development of its lead compound, CIC-39, targeting Duchenne Muscular Dystrophy (DMD) as its primary indication. DMD is a progressive pediatric condition leading to muscle degeneration and premature death, which highlights an urgent clinical need for effective therapies. The company is also expanding its research efforts to other chronic autoimmune and inflammatory conditions, such as Multiple Sclerosis (MS) and Systemic Lupus Erythematosus (SLE), leveraging CIC-39 and other compounds from its portfolio.

Industry Overview in Italy

The life sciences sector in Italy is experiencing significant growth, driven by advancements in biotechnology and pharmaceuticals. The country is home to a robust network of research institutions, universities, and innovative